By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AcelRx Pharmaceuticals 

575 Chesapeake Drive

Redwood City  California  94063  U.S.A.
Phone: 650-216-3500 Fax: 650-216-6500




Company News
AcelRx (ACRX) Appoints Vincent J. Angotti Chief Executive Officer 2/17/2017 9:06:30 AM
AcelRx (ACRX) Provides Guidance On 2017 Milestones For ARX-04, Now Known As DSUVIA In The United States, For The Treatment Of Moderate-To-Severe Acute Pain 1/9/2017 7:32:11 AM
AcelRx (ACRX) Announces DSUVIA As Brand Name For ARX-04 In The United States 1/9/2017 7:31:01 AM
AcelRx (ACRX) Submits New Drug Application For ARX-04 For The Treatment Of Moderate-To-Severe Acute Pain 12/13/2016 6:16:03 AM
AcelRx (ACRX) Reports On ARX-04 Market And Landscape Presented At Analyst & Investor Event 12/6/2016 7:31:05 AM
AcelRx (ACRX) Provides Corporate Update And Reports Third Quarter And Nine Months 2016 Financial Results 11/2/2016 8:15:06 AM
AcelRx (ACRX) To Hold Third Quarter Financial Results Conference Call And Webcast On Tuesday, November 1st, 2016 10/25/2016 9:30:59 AM
AcelRx (ACRX) Presenting ARX-04 Clinical Trial Findings And Cost Analysis At European Congress On Emergency Medicine 9/28/2016 10:21:52 AM
AcelRx (ACRX) Initiates Phase 3 Study Of Zalviso In Patients With Moderate-To-Severe Acute Post-Operative Pain 9/27/2016 7:19:38 AM
Findings From AcelRx (ACRX)' Phase 3 SAP301 Study Of ARX-04 In Abdominoplasty Patients To Be Presented At Plastic Surgery Meeting 9/23/2016 6:50:37 AM